NCT04357535View on ClinicalTrials.gov

Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives

CompletedOBSERVATIONAL
Enrollment

314

Participants

Timeline

Start Date

May 10, 2020

Primary Completion Date

July 1, 2020

Study Completion Date

August 1, 2020

Conditions
COVID-19
Interventions
DRUG

Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)

ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.

Trial Locations (1)

11211

King Faisal Specialist Hospital & Research Centre, Riyadh

All Listed Sponsors
collaborator

Buraidah Central Hospital

OTHER_GOV

collaborator

King Khalid University Hospital

OTHER

collaborator

Princess Nourah Bint Abdulrahman University

OTHER

lead

Hakeam Abdulaziz Hakeam

OTHER

NCT04357535 - Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives | Biotech Hunter | Biotech Hunter